Stricture formation after esophageal endoscopic resection has a negative impact on patients' quality of life because it causes dysphagia and requires multiple endoscopic dilations. Various methods by which to prevent stricture have recently been developed and reported. Among these methods, local steroid injection is the most commonly used and is currently considered the standard method for noncircumferential resection. However, local steroid injection has a limited effect on circumferential resection. Thus, oral steroid administration is used for such cases because it may have a stronger effect than local injection. Steroid treatment, both by local injection and oral administration, is effective and low-cost; however, it may cause fragility of the esophageal wall, resulting in adverse events such as perforation during balloon dilatation. Many innovative approaches have been developed, such as tissueshielding methods with polyglycolic acid, tissue engineering approaches with autologous oral mucosal epithelial cell sheet transplantation, and stent insertion. These methods may be promising, but they are limited by a scarcity of data. Further investigations are needed to confirm the efficacy of these methods.
INTRODUCTION
E SOPHAGEAL CANCER IS the sixth most common cause of cancer-related mortality worldwide. 1 The overall survival of patients with advanced esophageal cancer is poor. However, a favorable prognosis is expected if this cancer is detected at an early stage. [2] [3] [4] Endoscopic resection (ER) is widely used for the treatment of early-stage esophageal cancer because of its minimal invasiveness and good clinical outcome. 2 Endoscopic submucosal dissection (ESD) is an ER method that was developed around the year 2000. 5 ESD enables en bloc resection of large lesions and precise estimation of histology. Since the development of ESD, the indications for ER have gradually been extended to include larger lesions that were previously treated by surgery.
Although ER is an effective treatment, widespread esophageal ER can lead to postoperative esophageal strictures. Previous studies have shown that a mucosal defect involving more than 3/4 of the esophageal circumference after ER is a risk factor for stricture development. [6] [7] [8] Stricture rates after circumferential and noncircumferential resection are reportedly 100% and 56% to 76%, respectively [9] [10] [11] [12] [13] [14] , and the required numbers of dilatations are 13-23 and 6-9, respectively. [9] [10] [11] [12] Difference in the outcome after whole circumferential resection and noncircumferential resection is partly explained by differences in the healing process. After circumferential resection, epithelial regeneration occurs only from the oral and anal sides of the ulcer, whereas after noncircumferential resection, epithelial regeneration occurs from the oral side, anal side, and streak ( Fig. 1) . Therefore, it is generally considered that we should avoid whole circumferential resection in patients with semicircumferential esophageal cancer.
Stricture formation after ER has a negative impact on patients' quality of life because it causes dysphagia and requires multiple endoscopic dilations. 15 Ezoe et al. reported that prophylactic endoscopic balloon dilatation (EBD) was the treatment of choice to prevent stricture formation. However, stricture occurred in 59% of patients even after six preventive EBD sessions, and the median number of additional EBD sessions required after stricture formation was eight. 16 These results were not satisfactory, and more effective treatments have since been introduced.
STEROID THERAPY
Suppression of stricture formation by steroid administration S CAR FORMATION IS thought to be an integral part of wound healing, which is a process involving inflammation, proliferation, and remodeling. Collagen is the major fibrous connective tissue protein and provides structural support in scars. 17 Theoretically, steroids are the most suitable therapeutic agents for scars because of their ability to attenuate the inflammatory process and reduce collagen synthesis and fibroblast proliferation. 18, 19 Thus, previous reports on stricture prevention after esophageal ESD have mainly focused on the administration of steroids, [9] [10] [11] 14, [20] [21] [22] [23] [24] [25] [26] [27] both by systemic oral administration and direct local injection. Previous systemic reviews confirmed that steroid therapy achieves a significantly lower stricture rate and requirement for fewer EBD sessions without increasing complications. 28, 29 Oral steroid administration Yamaguchi et al.
14,20 described oral prednisolone administration to prevent stricture formation after esophageal ESD. They gave oral prednisolone at 30 mg/day on the third day post-ESD, gradually tapered this dose (30, 30, 25, 25, 20, 15, 10 , and 5 mg for 7 days each), and then discontinued the prednisolone 8 weeks later. Kataoka et al. 23 also reported oral prednisolone administration starting with 30 mg; they then tapered the dose by 10 mg every week and discontinued the prednisolone 3 weeks later. Stricture rates after giving oral prednisolone were 10%-14% for noncircumferential lesions and 27%-33% for circumferential lesions. These rates were much lower than those in the historical control groups without steroid treatment. Oral prednisolone administration may be effective; however, treatment with systemic steroids, especially at high oral doses, may raise concerns associated with various adverse effects. Decreasing the dose of systemic steroids may attenuate the adverse effects of steroids; it may also reduce the efficacy. Further investigation of the optimal dose of oral steroid administration is required.
Local steroid injection
Local steroid injection is applied based on the concept that inflammation and fibrosis after esophageal ESD can be inhibited by the direct administration of steroids to the ulcer site with a lower steroid dose than that used in systemic administration. [9] [10] [11] [24] [25] [26] [27] For this purpose, all authors in the present literature review used triamcinolone acetonide (TA) as the preferred agent. TA is a topical steroid that is gradually absorbed from the injected site over a few weeks. This drug is used for treatment of various conditions, including skin disease, oral aphthous ulcers, allergic rhinitis, and arthritis. Hashimoto et al. 24 reported that local TA injection into the ulcer site prevents esophageal strictures after ESD. In their study, stricture rate in the patients who received the local injection was 19% (4/21 patients). Hanaoka et al.
25 also reported that a single 100-mg local injection of TA immediately after ESD prevented esophageal strictures after ESD.
Local TA injection for noncircumferential lesions showed favorable outcomes in some studies, 20, 26, 27 whereas stricture rates were rather high in other studies (Table 1) . [9] [10] [11] In the assessment of treatment efficacy, extent of mucosal defect may affect stricture rates. Usually, a larger mucosal defect may result in a higher stricture rate, whereas a smaller mucosal defect may result in a lower stricture rate. We therefore showed extent of mucosal defect in Table 1 . When we examine the relationship between injection dose and stricture rate, lower doses seem to be associated with worse outcomes. From the viewpoint of efficacy, TA injection of ≥80 mg should probably be recommended. Although local TA injection showed a favorable effect for noncircumferential lesions, the outcome of whole circumferential lesions was unfavorable. In particular, a single local TA injection failed to prevent stricture in almost all cases of whole circumferential resection. Therefore, oral steroid administration or combination treatment involving local TA injection with another alternative treatment should be considered for whole circumferential lesions.
Adverse events associated with steroid therapy
Possible adverse events associated with steroid administration include immunosuppression, diabetes, psychiatric disorders, osteoporosis, optical damage, and peptic ulcer disease. Immunosuppression may cause infection such as Candida esophagitis and pneumocystis pneumonia. 36 The occurrence of rare infection such as disseminated nocardiosis 37 has also been reported. Because the literature supports prophylaxis for pneumocystis pneumonia in patients given steroids at doses of >20 mg for 1 month or longer, prophylaxis against bacterial infection is usually given during the treatment. 38 Fragility of the esophagus is another problem associated with steroid treatment. Animal studies have shown dense fibrosis in the submucosal area and atrophy of the muscularis propria after steroid injection. 39, 40 In one clinical study, a deep submucosal tear without perforation occurred when the endoscope was passed through the narrow space formed by the post-ESD scar in a patient who received local TA injection. 25 Other authors have reported a higher risk of perforation in balloon dilation among patients undergoing steroid treatment. 26, 41 Careful balloon dilatation, such as that using a small-caliber balloon or low inflation pressure, is advised after steroid treatment.
Effective use of oral steroid administration and local steroid injection
Previous reports indicate that after whole circumferential resection, oral steroid administration may be a preferred treatment method because local TA injection failed to prevent stricture [9] [10] [11] 20, 26 (Table 2 ). Combination treatment involving oral steroid administration and local TA injection is also being evaluated at some facilities. 9, 44 Both oral steroid administration and local TA injection showed favorable effects for noncircumferential lesions (Table 1) . [9] [10] [11] 20, 23, 26, 27 Some researchers have stated that local TA injection requires a highly skilled technique; however, it is not difficult for endoscopists who can carry out ESD for large lesions. Moreover, local TA injection is quite simple because the treatment can be completed on the day of ESD. Oral steroid administration is somewhat burdensome for the patient and doctors because regular intake of steroids is required for at least 8 weeks along with bacterial prophylaxis. The steroid dosage as well as possible adverse events such as diabetes and psychiatric disorders should be monitored regularly. Considering the efficacy and convenience of the treatment, local TA injection is currently the most common treatment conducted for noncircumferential lesions in Japan.
A multicenter prospective randomized controlled trial (JCOG1217) is underway to compare the efficacy of prophylactic oral steroid administration and local TA injection for patients with noncircumferential lesions. 45 If the superiority of oral steroid administration is confirmed, this method will be the standard treatment for the prevention of strictures after esophageal ESD. However, when we consider the high feasibility of local TA injection, this method will still be used in situations when it is considered effective. Accurate prediction of the effect of local TA injection is important to ensure the effective use of both oral steroid administration and local TA injection.
Modified steroid method
Modified steroid treatments are being tested to overcome limitations of the local injection method or oral administration method. 33, 46, 47 A TA-filling method, which maintains a saline solution of TA in the esophagus for a certain time to infiltrate TA into the ulcer, was recently reported. This procedure was carried out on days 1 and 7 and when mild stenosis was found on follow up. The incidence of severe stricture was 4.5% (1/22 cases; Table 2 ). The outcome was among the best among steroid treatment techniques. This method seems promising; however, it has been conducted in only one facility. Confirmation of the treatment effect in a multicenter setting is recommended.
POLYGLYCOLIC ACID SHEETS
A POLYGLYCOLIC ACID (PGA) sheet is a biodegradable suture stiffener that has been used to reinforce sutures in implantation surgeries, repair mucosal defects, prevent scar contracture, and alleviate postoperative pain. [48] [49] [50] [51] The purpose of using PGA after esophageal ESD is to prevent stricture by protecting the wound surface from contact with exogenous materials and suppressing subsequent organization of the granulation tissue.
Two studies from Japan 30,31 evaluated the efficacy of PGA sheets in preventing strictures in patients who had undergone noncircumferential resection ( Table 1) . The sheets were attached with fibrin glue over the surgical wound immediately after completion of ESD (Fig. 2) . Esophageal strictures occurred in 7.7% (1/13) of patients with mucosal defects of ≥1/2 of the esophageal circumference 30 and in 37.5% (3/8) of patients with mucosal defects of ≥3/4 of the esophageal circumference. 31 Adverse event rates associated with this method were low in both studies. Considering its methodological complexity and higher cost compared with local TA injection, the result was not satisfactory. In addition, this method is minimally effective for patients undergoing whole circumferential resection.
The efficacy of combined therapy using local TA injection and PGA sheets for further improvement of outcomes was evaluated in some studies. 34, 35 In these studies, TA was injected into the ulcer immediately after ESD, and this was followed by shielding of the ulcer with Digestive
PGA sheets and fibrin glue. The results were favorable, with a stricture rate of 11%-25% for noncircumferential lesions and 1/2 to 2/3 for whole circumferential lesions. However, these studies included only small numbers of patients. Further large-scale studies are needed to confirm the superiority of combined therapy using local TA injection.
ESOPHAGEAL STENTS E SOPHAGEAL STENTS WERE initially used as a minimally invasive treatment for esophageal fistula and unresectable malignant esophageal stenosis. [52] [53] [54] Several recent studies have demonstrated the use of temporary selfexpandable metallic stents to treat esophageal benign conditions 55, 56 and showed that stent implantation effectively alleviates the degree of stricture and stricture symptoms. In contrast, some studies showed that the incidence of complications such as granulation tissue hyperplasia, chest pain, and stent displacement was relatively high. 57, 58 To prevent stricture formation after esophageal ESD, Wen et al. 59 placed a stent immediately after ESD and removed it 8 weeks later in patients with a mucosal defect of ≥3/4 of the esophageal circumference. The stricture rate was 18% (2/11 patients). Ye et al. 42 placed a stent immediately after ESD and removed it 3 months later in patients who had undergone whole circumferential resection. The stricture rate was 17% (4/23 patients). Although the expected efficacy was confirmed in these two studies, Holt et al. 43 showed disappointing results. They placed a stent 10 days after ESD and removed it 8 weeks after ESD in patients who had undergone whole circumferential resection. The stricture rate was 57% (8/14 patients).
Application of metallic esophageal stents for treatment of benign esophageal strictures is controversial because of common adverse events such as bleeding, esophageal perforation, stent migration, and stricture recurrence. 54, 60 Considering the complexity of the treatment, high adverse event rate, and favorable outcome by other preventive methods such as steroid therapy, stents are not indicated in patients who have undergone noncircumferential resection. However, stricture formation after circumferential resection is still difficult to prevent using conventional methods such as local TA injection, oral steroid administration, or PGA sheets. Thus, stent placement is a good option after circumferential resection or for treatment of refractory strictures. For further improvement of stent treatment, biodegradable esophageal stents have been developed and used to treat refractory benign esophageal strictures.
61-63
The efficacy of biodegradable stents is being evaluated in various situations including refractory stricture after ER.
OTHER METHODS USING CONVENTIONAL DRUGS OR MATERIALS
S TUDIES HAVE BEEN carried out to evaluate the stricture-prevention ability of various drugs that may inhibit inflammation and collagen synthesis, such as the antiallergic agent tranilast 64 and the antineoplastic drugs mitomycin C and 5-fluorouracil. 65, 66 Tranilast and 5-fluorouracil showed efficacy in preventing stricture; however, no further investigation has been conducted for >5 years since the initial studies of these drugs.
Botulinum toxin type A (BXT-A) is a neurotoxin that inhibits the deposition of collagen fibers and improves hypertrophic scars. 67 Gassner et al. 68 initially showed that a single injection of BTX-A improved the cosmetic appearance of cutaneous scars. To investigate the prevention of stricture formation after esophageal ESD, Wen et al. 32 conducted a randomized study involving 67 patients. They included patients with mucosal defects of ≥1/2 of the esophageal circumference after ESD. Percentage of post-ESD strictures in the BTX-A group (11%, 4/35 patients) was significantly lower than that in the control group without injection (38%, 14/37 patients; P < 0.05). No serious adverse events associated with BTX-A injection occurred. In this randomized study, the efficacy of BTX-A injection was confirmed. However, most of the included patients had a mucosal defect of <3/4 of the esophageal circumference. Only six patients in the study group had a mucosal defect of ≥3/4, but the defect was not circumferential. Thus, the efficacy of this treatment should be confirmed in a larger study that mainly includes patients with mucosal defects of ≥3/4 of the esophageal circumference.
TISSUE ENGINEERING APPROACHES
T ISSUE ENGINEERING IS based on the concept that transplanted materials can replace damaged tissues and maintain the physiological functions and induce scarless wound healing. 69 Tissue engineering approaches with which to prevent esophageal strictures are divided into two groups: cell-based therapy and scaffold-based therapy (Table 3) . 
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Cell-based therapy
Cell-based therapies are expected to have trophic effects on the host as the transplanted cells release cytokines and growth factors and interact with other host cells. Direct injection of keratinocytes or adipose stromal cells into the host organ was initially evaluated. Direct injection of autologous buccal keratinocytes suppressed stricture formation after ER in a pig model, 78 and direct injection of adipose tissue-derived stromal cells also suppressed stricture formation after ER in a canine model. 79 Although both methods were effective, direct injection of primary cells into the host organ has two major disadvantages: low viability and rapid diffusion from the host sites after transplantation. To overcome such limitations, Perrod et al. transplanted adipose tissue-derived stromal cell sheets to the resection site and showed a decreased stricture rate after ESD in a porcine model. 71, 80 Ohki et al. 70 evaluated the use of autologous oral mucosal epithelial cell sheets in patients with mucosal defects of ≥1/2 (Table 3) . They fabricated epithelial cell sheets in an ex vivo technique and endoscopically transplanted the sheets directly onto the ulcer surfaces. Complete re-epithelialization occurred within a median time of 3.5 weeks. A stricture developed in only one patient who had undergone whole circumferential resection. Although this method is promising, the operating cost is high (currently estimated to be at least 20 000 to 30 000 USD per case). More clinical evaluations should be carried out to ensure the safety and cost-effectiveness of cell-based therapy.
Scaffold-based therapy
Extracellular matrix (ECM) scaffolds can support the growth of epithelial cells and promote wound recovery. 81 ECM scaffolds derived from the small intestinal submucosa or urinary bladder submucosa were reportedly used for successful reconstruction of the esophagus in a canine model. 82 Acellular dermal matrix (ADM) is a type of ECM (Table 3) . 72 In a study involving human patients, Badylak et al. reported that ECM scaffolds prevented strictures in five male patients after endoscopic inner-layer circumferential resection. 83 Hoppo et al. 84 applied ECM scaffolds after circumferential ER, and strictures were prevented in three patients. Conversely, Schomisch et al. reported unsuccessful outcomes for the prevention of stricture formation using three ECM scaffolds: small intestinal submucosa, ADM, and urinary bladder matrix. 85 The efficacy of the ECM scaffold is still controversial. In addition, there are concerns that the scaffold material may lead to a higher risk of local recurrence or local infection because ECM is a favorable environment for the engraftment of cancer cells and bacteria. Thus, ECM needs additional critical testing before it is widely applied to clinical practice.
TRANSPLANTATION OF ESOPHAGEAL MUCOSA
L IAO et al. 77 recently described the performance of esophageal mucosal transplantation to prevent stricture formation after circumferential ESD. Several pieces of autologous esophageal mucosal tissue were excised by EMR from a normal esophagus and attached to the ulcer surface using hemoclips. They were then fixed with a covered stent, which was removed 7 days after the procedure. Although strictures developed in eight of nine patients, mean number of EBD sessions was 2.7 (range, 0-6). The number of EBD was much fewer than in previous reports. [9] [10] [11] [12] The concept of this treatment is quite unique and the result is promising. However, the technique is invasive in that multiple pieces of esophageal mucosa are removed and stent insertion is carried out. Moreover, an important concern is the possibility of carcinogenesis from the implanted esophageal mucosa. Based on the field cancerization theory, the surrounding mucosa of esophageal cancer also has a high risk of cancer. 86 MANAGEMENT OF STRICTURE E VEN AFTER PREVENTION, stricture sometimes develops after ER. Risk factors for stricture after local TA injection are reported to be: (i) mucosal defects of ≥5/ 6; 27 or (ii) tumor extent of ≥3/4. 26 Risk factors for stricture after oral steroid administration are reported to be: (i) mucosal defects of ≥11/12; (ii) longitudinal diameter of ≥50 mm; (iii) lesion in the cervical esophagus; and (iv) history of chemoradiotherapy. 20 Stricture after ER is usually treated by repeated balloon dilatation. TA injection into the laceration after balloon dilatation may lower the frequency of balloon dilatation. Recently, biodegradable esophageal stents have been developed and may be applied to the treatment of refractory strictures after ER. Compared with metallic or plastic stents, biodegradable stents are advantageous in that they do not need to be removed and have sufficient radial force to expand the esophagus. [61] [62] [63] However, the current evidence regarding biodegradable esophageal stents and TA injection after balloon dilatation is insufficient to determine their efficacy; therefore, further investigation is needed.
Future perspectives
More recent studies have evaluated the preventive effect of new materials such as carboxymethyl cellulose sheets, collagen vitrigel (a collagen-based biomaterial), conditioned medium obtained from mesenchymal stem cells, and small interfering RNA targeting carbohydrate sulfotransferase 15 (Table 3) .
(i) Carboxymethyl cellulose (CMC) sheet is a type of bioresorbable membrane consisting of hyaluronic acid and carboxymethyl cellulose. It is widely used in abdominal, epidural, and gynecological surgery to reduce postoperative adhesions. According to previous reports, it can reinforce the covered tissues, minimize scar contracture, and promote epithelial cell growth. 74 (ii) Collagen vitrigel is a collagen-based biomaterial consisting of high-density collagen fibrils equivalent to connective tissues in vivo that is created by a vitrification process. An artificial skin based on collagen vitrigel demonstrated the ability to promote epithelization of regenerative skin and inhibited scar formation and inflammation. 75 (iii) Mesenchymal stem cells are a valuable cell source in regenerative medicine, and conditioned medium obtained from mesenchymal stem cells reportedly inhibits inflammation. 76 (iv) Carbohydrate sulfotransferase 15 (CHST15) is a type II transmembrane Golgi protein that biosynthesizes highly sulfated disaccharide units of chondroitin sulfate into ECM. Blockade of CHST15 by small interfering RNA (siRNA) reportedly repressed fibrosis. 73 These materials showed promising effects to prevent stricture in animal models. Further evaluation in humans is needed before its clinical use.
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